Abstract
OBJECTIVES: To evaluate the long-term efficacy of treating nasal telangiectasias with the TRASER device.
METHODS: Subjects from the TRASER efficacy analysis clinical trial were invited for a 1-year follow-up. Standardized photographs were taken to compare to baseline. The same clinical trial evaluator graded the subjects' current vessel clearance using the 5-point telangiectasia scale. The data was compiled and analyzed.
RESULTS: Of the subjects with available follow-up data, 44% maintained "complete vessel clearance," 44% dropped down one grade to "almost complete vessel clearance," and 11% dropped down to "moderately clear vessel clearance." All showed clinically significant improvement in nasal telangiectasias from baseline.
CONCLUSIONS: The TRASER effectively treats nasal telangiectasias with minimal to mild recurrence at 1-year follow-up. Lasers Surg. Med. 50:61-63, 2018. © 2017 Wiley Periodicals, Inc.
Original language | English (US) |
---|---|
Pages (from-to) | 61-63 |
Number of pages | 3 |
Journal | Lasers in Surgery and Medicine |
Volume | 50 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2018 |
Keywords
- TRASER
- laser
- telangiectasias
- vessels
ASJC Scopus subject areas
- Surgery
- Dermatology